相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
Satoshi Ikeda et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease
Hirotsugu Kenmotsu et al.
CANCER SCIENCE (2019)
The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease
Yuichiro Yasuda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias
Tetsuo Fujita et al.
INTERNAL MEDICINE (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease
Masaki Hanibuchi et al.
LUNG CANCER (2018)
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
Satoshi Igawa et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Anticancer drug treatment for advanced lung cancer with interstitial lung disease
Kohei Otsubo et al.
RESPIRATORY INVESTIGATION (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Clinical significance of post-progression survival in lung cancer
Hisao Imai et al.
THORACIC CANCER (2017)
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
H. Nokihara et al.
ANNALS OF ONCOLOGY (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study
Akimasa Sekine et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer
Hisao Imai et al.
THORACIC CANCER (2016)
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
Hirotsugu Kenmotsu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease
Moon Ki Choi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial
Yasuhide Yamada et al.
LANCET ONCOLOGY (2013)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia
Takashi Kinoshita et al.
ONCOLOGY LETTERS (2012)
The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report
Hiromichi Yamane et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2011)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pulmonary toxicity by a cytotoxic agent, S-1
Yuji Tada et al.
INTERNAL MEDICINE (2007)
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
A Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Interstitial lung disease associated with drug therapy
P Camus et al.
BRITISH JOURNAL OF CANCER (2004)
The epidemiology of interstitial lung disease and its association with lung cancer
G Raghu et al.
BRITISH JOURNAL OF CANCER (2004)
Idiopathic interstitial pneumonia - What is the effect of a multidisciplinary approach to diagnosis?
KR Flaherty et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis
GW Hunninghake et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: First case report
E Kurakawa et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
